Drugs / RTS,S/AS02D
last change Dec 2007 re-read 2 minutes ago

RTS,S/AS02D

also known as GSK 257049

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00197028 Aug 2005 → Dec 2007 Plasmodium falciparum malaria GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS02D ClinicalTrials.gov intervention name — accepted as the source's own label NCT00197028
Known as GSK 257049 “the candidate malaria vaccine, GSK 257049 vaccine (0.5 ml dose)” NCT00197028
Modality Vaccine “candidate malaria vaccineNCT00197028